Fluorescence in situ hybridization versus immunohistochemistry: importance of clinical outcome

Comparative Study

S Seelig. J Clin Oncol. 1999 Nov.

. 1999 Nov;17(11):3690-2.

doi: 10.1200/JCO.1999.17.11.3690.

No abstract available

Comment on

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Jacobs TW, et al. J Clin Oncol. 1999 Jul;17(7):1974-82. doi: 10.1200/JCO.1999.17.7.1974. J Clin Oncol. 1999. PMID: 10561247
Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Jacobs TW, et al. J Clin Oncol. 1999 Jul;17(7):1983-7. doi: 10.1200/JCO.1999.17.7.1983. J Clin Oncol. 1999. PMID: 10561248